MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
The DSMB recommended that the trial continue without modifications.
- The DSMB recommended that the trial continue without modifications.
- The DSMB, composed of 4 independent experts, including an ALS patient association representative, concluded that safety was good.
- More precisely, it should be noted that no serious or severe adverse events were observed, and no infectious events could be related to MaaT033.
- The preliminary results reinforce confidence in the safety of MaaT033, a drug candidate produced by combining the microbiota from multiple donors using a "pooling" process.